BioXcel Therapeutics, Inc. Net Change in Cash
BioXcel Therapeutics, Inc. (BTAI) reported Net Change in Cash of -$14.96 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-13
- BioXcel Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$11.58M, a 1098.88% decline year-over-year.
- BioXcel Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $1.16M, a 87.01% decline year-over-year.
- BioXcel Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $8.92M.
- BioXcel Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$28.20M.
- BioXcel Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$1.10M.
- BioXcel Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$35.37M.
- BioXcel Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$128.50M.
- BioXcel Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$39.24M, a 297.71% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$14.96M 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | -$11.58M 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | -$1.10M 10-K · filed 2026-03-27 | |||
| 2025-09-30 | $7.47M 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | -$11.28M 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | $1.16M 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | -$35.37M 10-K · filed 2026-03-27 | |||
| 2024-09-30 | -$24.83M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | -$8.95M 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | $8.92M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | -$128.50M 10-K · filed 2025-03-28 | |||
| 2023-09-30 | -$103.76M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$66.18M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | -$28.20M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$39.24M 10-K · filed 2024-03-22 | |||
| 2022-09-30 | -$654.00K 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | $484.00K 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$32.53M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $19.85M 10-K · filed 2023-03-16 | |||
| 2021-09-30 | $39.79M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $59.94M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | -$19.10M 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $180.69M 10-K · filed 2022-03-11 | |||
| 2020-09-30 | $201.00M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $33.07M 10-Q · filed 2021-08-10 | |||
| 2020-03-31 | $47.65M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | -$10.14M 10-K · filed 2021-03-12 | |||
| 2019-09-30 | -$2.31M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | -$12.60M 10-Q · filed 2020-08-14 | |||
| 2019-03-31 | -$6.27M 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $41.68M 10-K · filed 2020-03-09 | |||
| 2018-09-30 | $46.23M 10-Q · filed 2019-11-14 | |||
| 2018-06-30 | $49.46M 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | $54.58M 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | $887.00K 10-K · filed 2019-03-12 | |||
| 2017-09-30 | $754.00K 10-Q · filed 2018-11-09 | |||
| 2017-06-30 | $285.00K 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |